Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bumetanide is a potent loop diuretic (water pill) used primarily to treat edema (fluid retention) associated with congestive heart failure, liver disease, kidney disease, and nephrotic syndrome. It acts by inhibiting sodium and chloride reabsorption in the ascending limb of the loop of Henle in the kidney, leading to increased excretion of water, sodium, chloride, and potassium. This results in diuresis and reduction of fluid overload. Bumetanide is considered more potent than furosemide on a per-milligram basis and has more predictable pharmacokinetics. It is available as oral tablets or injectable solutions[1][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bumetanide.